Abstract

Modern incretin mimetics such, Glucagon like peptide 1 receptor agonists (GLP 1RAs) produce substantial weight loss and metabolic improvements in obesity and type 2 diabetes, but a meaningful portion of weight reduction may include lean body mass. Preservation of skeletal muscle and functional capacity requires integration of resistance (anaerobic) and aerobic exercise with targeted nutritional strategies, especially adequate protein intake and correction of key micronutrient deficits. This mini review summarizes current evidence and practical recommendations for combining GLP 1RA therapy with exercise and clinical nutrition to optimize body composition and functional outcomes..

Keywords: Incretin Mimetics; GLP 1 Receptor Agonists; Obesity; Exercise; Body Composition; Lean Mass; Clinical Nutrition; Resistance Training; Protein

Abbreviations: GLP 1Ras: Glucagon like peptide 1 receptor agonists

Introduction

GLP 1RAs (e.g., semaglutide, liraglutide) and dual incretin agonists (e.g., tirzepatide) have transformed pharmacologic management of obesity and type 2 diabetes, demonstrating large, sustained weight losses and metabolic benefits in randomized trials [1,2]. However, trials and observational studies indicate that 20–30% of total weight loss can reflect reductions in fat free mass, raising concerns about muscle preservation, functional performance, and long-term metabolism [3-5,8,9].

Effects of GLP 1ras On Body Composition

This incretin mimetic produces mean relative weight losses substantially greater than older agents, with preferential fat mass reduction but concurrent losses of lean tissue in many patients [1,2,5,8,9]. Lean mass loss during rapid or large weight reduction is a known phenomenon of maladaptive response and has implications for strength, resting energy expenditure, and resilience-particularly in older adults and those with baseline sarcopenic obesity [9].

Role Of Exercise During GLP 1RA Therapy

Resistance (Anaerobic) Training: Primary strategy to preserve or increase skeletal muscle during energy deficit. Evidence supports that combining pharmacologic weight loss treatments with resistance exercise mitigates loss of fat free mass and improves strength and function [6,10].
Practical Prescription: 2–3 sessions/week targeting major muscle groups, 2–4 sets of ~6–12 repetitions with progressive overload; include compound movements and, when appropriate, power training for older adults.

Aerobic Training

Supports cardiovascular fitness, increases total energy expenditure, and improves cardiometabolic risk factors. Guidelines generally recommend 150–300 min/week of moderate or 75–150 min/week of vigorous activity, individualized to tolerance.

Combination Benefits

Concurrent resistance plus aerobic programs typically provides superior improvements in body composition, cardiorespiratory fitness, and metabolic markers compared with either modality alone [6]. Supervision and gradual progression improve adherence, especially during initial GLP 1RA dose titration when nausea or fatigue may limit activity.

Clinical Nutrition Considerations

Protein: Adequate protein intake is central to preserving lean mass during weight loss. During pharmacologically induced appetite suppression, prioritize high quality, leucine rich proteins and distribute protein across meals with attention to post exercise intake.
Energy Deficit: Avoid excessively aggressive caloric deficits that accelerate muscle loss; pair moderate deficits with resistance exercise to favor fat relative to lean mass loss.
Micronutrients and Supplements: Monitor and correct deficiencies of vitamin D, iron, and B12 when indicated, given their roles in muscle function and overall health. Consider evidencebased adjuncts (e.g., creatine adjunct to resistance training) on an individualized basis.
Practical Measures for Tolerability: GLP 1RA–related GI effects and appetite suppression require meal planning focused on nutrient density and protein rich, smaller frequent meals. Dietitian involvement improves adequacy and adherence.

Clinical Implications and Monitoring

Adding supervised exercise to pharmacological obesity treatment appears to enhance long term weight stability after stopping therapy compared with stopping medication alone. Participants who completed supervised exercise-maintained body weight and composition at one year post intervention, whereas those who only received pharmacotherapy experienced weight regain [11]. Baseline and periodic assessment: body composition (DXA or validated BIA), muscle strength (handgrip), and functional tests (timed up and go, chair rise) to detect and address lean mass loss.

Safety: monitor for exercise intolerance during drug titration and adjust glucose lowering regimens (insulin/sulfonylureas) to mitigate hypoglycemia when activity increases.

Multidisciplinary Care: coordination among prescribing clinicians, dietitians, and exercise specialists optimizes outcomes and safety.

Current Evidence Gaps

While trials document lean mass losses with GLP 1RAs, randomized studies specifically evaluating structured resistance training and optimized nutrition during GLP 1RA therapy are limited and heterogeneous. Long-term data on functional outcomes and sarcopenia risk are needed.

Recommendations

Before and during GLP 1RA therapy: assess body composition and function; prescribe supervised resistance training 2–3×/week plus regular aerobic activity. Ensure adequate protein (prioritize high quality protein and distribute intake across meals) and correct vitamin D and other deficiencies when present. Use a multidisciplinary approach and monitor for hypoglycemia adjustments in patients with diabetes.

Conclusion

GLP 1RAs are powerful agents for weight reduction and metabolic improvement, but optimizing the quality of weight loss requires concurrent exercise (with emphasis on resistance training) and targeted nutritional strategies to preserve lean mass and functional capacity. Multidisciplinary, monitored interventions should be integrated into clinical care for patients receiving GLP 1RA therapy.

Conflict of Interest

The authors declare that they have no conflict of interest.

References

1. John P H Wilding, Rachel L Batterham, Salvatore Calanna, Melanie Davies, Luc F Van Gaal, et al. (2021) Once weekly semaglutide in adults with overweight or obesity. N Engl J Med 384(11): 989-1002.
2. Ania M Jastreboff, Louis J Aronne, Nadia N Ahmad, Sean Wharton, Lisa Connery, et al. (2022) Tirzepatide once weekly for the treatment of obesity. N Engl J Med 387(3): 205-216.
3. Drucker DJ (2018) Mechanisms of action and therapeutic application of glucagon like peptide 1. Cell Metab 27(4): 740-756.
4. Melanie J Davies, Richard Bergenstal, Bruce Bode, Robert F Kushner, Andrew Lewin, et al. (2015) Efficacy of liraglutide for weight management in patients with type 2 diabetes: the SCALE diabetes randomized clinical trial. JAMA 314(7): 687-699.
5. Sencar ME, et al. (2022) Effectiveness of semaglutide on body composition in obese patients with type 2 diabetes. Nutrients 14: 2414.
6. Julie R Lundgren, Charlotte Janus, Simon BK Jensen, Christian R Juhl, Lisa M Olsen, et al. (2021) Healthy weight loss maintenance with exercise, liraglutide, or both combined. N Engl J Med 384(18): 1719-1730.
7. Buse JB, Garber AJ, Rosenstock J, et al. (2021) Tirzepatide versus insulin glargine in type 2 diabetes. Lancet. 398(10313): 1811-1824.
8. Ian J Neeland, Jennifer Linge, Andreas L Birkenfeld (2024) "Changes in lean body mass with glucagon‐like peptide‐1‐based therapies and mitigation strategies." Diabetes, Obesity and Metabolism 26(Suppl 4): 16-27.
9. Jennifer Linge, Andreas L Birkenfeld, Ian J Neeland (2024) Muscle mass and glucagon-like peptide-1 receptor agonists: adaptive or maladaptive response to weight loss ?." Circulation 150(16): 1288-1298.
10. João Carlos Locatelli, Juliene Gonçalves Costa, Andrew Haynes, Louise H Naylor, P Gerry Fegan, et al. (2024) Incretin-based weight loss pharmacotherapy: can resistance exercise optimize changes in body composition.? Diabetes Care 47(10): 1718-1730.
11. Simon Birk Kjær Jensen, Martin Bæk Blond, Rasmus Michael Sandsdal, Lisa Møller Olsen, Christian Rimer Juhl, et al. (2024) Healthy weight loss maintenance with exercise, GLP-1 receptor agonist, or both combined followed by one year without treatment: a post-treatment analysis of a randomized placebo-controlled trial." E Clinical Medicine 69: 102475.